Purification and characterization of a naturally occurring activator of cholesterol biosynthesis from delta 5,7-cholestadienol and other precursors.
Explore the source record for details and available documents.
Animals↗
SEARCH · Search PubMed
Results for “Cholestadienols”
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Pathway of cholesterol biosynthesis in the brain of the neonatal rat.
Suckling rats were killed at various intervals after intraperitoneal injection of acetate-1-(14)C and their brain sterols were analyzed by column, thin-layer, paper, and gas-liquid chromatography. The crude sterol (to which carrier zymosterol was added) was separated by column chromatography into cholesterol, desmosterol, and zymosterol fractions, and the specific activities of the recovered digitonides were determined. The zymosterol fraction, mainly carrier, was not uniformly labeled, in that the trailing half of the peak had a higher specific activity than the leading half. Evidence obtained suggests that this carbon activity was present in one or more sterols resembling zymosterol (Delta(8,24)-cholestadienol), Delta(7,24)-cholestadienol, and Delta(7,5.24)-cholestatrienol. The desmosterol and cholesterol were also carbon-labeled. The time course of the distribution of carbon activity among the above fractions indicated that the zymosterol fraction is a precursor of the desmosterol and that the desmosterol is, in turn, a precursor of the cholesterol. The data suggest that, in the developing brain of the rat, the course of the transformation of cholesterol precursors into cholesterol is influenced by the presence of at least two slow steps, one involving the conversion of Delta(7)- and Delta(8)-compounds to Delta(5)-compounds and the other, the reduction of the Delta(24)-unsaturation.
Animals↗
Synthesis of delta 5,22-cholestadien-3 beta-ol from delta 5,7,22-cholestatrien-3 beta-ol by a liver enzyme.
The rat liver enzyme system, which catalyzes reduction of delta 5,7,24-cholestatrien-3 beta-ol to cholesterol (delta 5-cholesten-3 beta-ol), converted radiolabeled delta 5,7,22-cholestatrien-3 beta-ol to delta 5,22-cholestadien-3 beta-ol, but not to cholesterol. This enzyme system thus contains membrane-bound delta 7- and delta 24-reductase and no delta 22-reductase. Kinetic and competition studies showed that the enzyme system contains a single delta 5,7-sterol delta 7-reductase, which is not influenced by unsaturation at the delta 22-position of the sterol side chain. The identity of delta 5,22-cholestadienol was established by chromatographic, spectral and chemical analyses. Use of the enzyme system and readily available delta 5,7,22-cholestatrienol provides a facile procedure for specific production of delta 5,22-cholestadien-3 beta-ol in quantity.
Animals↗
Identification of delta 5,7-sterol-delta 7-reductase in higher plant microsomes.
A microsomal preparation from seedlings of Zea mays catalyzed the NADPH dependent reduction of the delta 7-bond of delta 5,7-cholestadienol (1) giving the first in vitro evidence for the intermediacy of delta 5,7-sterols in plant sterol biosynthesis. Using a GC assay developed to detect the cholesterol (2) produced, the properties of the microsomal enzyme have been established with respect to cofactor requirements and kinetics. The potent in vitro inhibition of the plant delta 5,7-sterol-delta 7-reductase by the ammonium-ion containing fungicides, tridemorph2 (3), fenpropimorph (4) and AY 9944 (5) was demonstrated. The high affinities observed for these derivatives, especially for (4) (I50 = 8 x 10(-8) M, I50/Km = 2 x 10(-4)), are in full accordance with the previously proposed cationic mechanism involved in this reduction reaction.
Cholesterol↗
Investigations of cholesterol transformation during sewage treatment: relevance to estrogen formation pathways?
There is currently a great deal of concern over the observation of so-called estrogenic effects (specifically increases in the concentrations of the egg yolk precursor, vitellogenin) in male fish living in some UK rivers. The effects have been attributed to chemicals, including estrogenic steroids, which enter the rivers via sewage effluents. The origins of these estrogenic steroids in sewage may include contributions from the influents and possibly in situ transformation processes of other steroids occurring during sewage treatment. The present study examined the latter possibility. The bacterial metabolism of radiolabelled cholesterol during laboratory-simulated aerobic sewage treatment was studied by reverse phase radio-high performance liquid chromatography (rHPLC) and radio-gas chromatography (rGC) to examine the hypothesis that cholesterol could undergo A-ring aromatisation to form first, 19-norcholest-1,3,5(10)-trien-3-ol (NCT) and hence, by known bacterial pathways, the estrogenic steroid, estrone. The results showed that, to the contrary, much of the cholesterol (approx. 50% in 96 h) underwent rapid mineralisation to carbon dioxide, consistent with A-ring rupture (rather than aromatisation) and beta-oxidation of the alkyl side chain as major transformation routes. Some polar (early-eluting) rHPLC products were observed, possibly steroidal conjugates and/or fatty acids. Among the minor metabolites detected by rGC and GC-mass spectrometry (GC-MS) were cholest-3,5-diene and a second cholestadiene isomer. However, since alkenes were unexpected in this rHPLC fraction, they may arise as artefacts from thermal decomposition of cholesteryl esters, indicating that some cholesterol esterification had also occurred. In the alcohol rHPLC fractions, cholestadienol was identified by GC and GC-MS but neither NCT or estrone were detected. This suggests that, at least under these simulated conditions, in situ aromatisation of cholesterol to NCT and formation of estrone from NCT were not major processes.
Animals↗
Aphidicolin, a specific inhibitor of DNA polymerase alpha, inhibits conversion of lanosterol to C-27 sterols in mouse L cells.
Aphidicolin, a fungal metabolite which is a specific inhibitor of DNA polymerase alpha, inhibited the incorporation of [14C]acetate into desmosterol in mouse L cells by 50% at a concentration of 8.8 microM. It had no effect on acetate metabolism into fatty acids or CO2. The site of inhibition was determined to be distal to the formation of mevalonic acid since aphidicolin also inhibited the incorporation of [14C]mevalonolactone into desmosterol but had no effect on the activity of 3-hydroxy-3-methylglutaryl-CoA reductase (EC 1.1.1.34) or the incorporation of [14C]acetate into total nonsaponifiable lipids. High pressure liquid chromotographic analysis of the distribution of radioactivity among the nonsaponifiable lipids formed from [14C]acetate in the presence of aphidicolin indicated an accumulation of lanosterol accompanied by a proportional decrease in radiolabeled desmosterol and two of its precursors, delta 5,7,24-cholestatrienol, and 4 alpha-methyl-delta 8,24-cholestadienol. In cells exposed to aphidicolin, lanosterol accumulation was rapid (15 min) and reversible after a 3-h exposure when cells were rinsed and fresh medium added. It was concluded that aphidicolin inhibits the conversion of lanosterol to C-27 sterols. Although the exact mechanism of this inhibition has not yet been determined, addition of aphidicolin to 20,000 X g supernatant fractions of mouse liver homogenates inhibited the incorporation of [14C]mevalonolactone into cholesterol in a concentration-dependent manner, suggesting that aphidicolin may act directly on one or more of the enzymatic steps involved in lanosterol demethylation. The ubiquitous occurrence of an aphidicolin binding site on eukaryotic DNA alpha polymerases and the inhibitory action of aphidicolin at a proposed secondary regulatory site in sterol biosynthesis (lanosterol metabolism) suggest that a naturally occurring compound may exist which can regulate both DNA replication and cholesterogenesis.
Acetates↗
Simvastatin treatment in the SLO syndrome: a safe approach?
Soon after the discovery of reduced cholesterol synthesis in the Smith-Lemli-Opitz syndrome (SLOS), several trials with dietary supplementation were initiated with the aim of increasing cholesterol and reducing the de novo synthesis and accumulation of 7- and 8-dehydrocholesterol (DHC). Dietary cholesterol raises cholesterol levels in the circulation with only marginal effects on levels of DHC. Photosensitivity and polyneuropathy have been reported to be improved by the treatment, but other effects have been difficult to evaluate. In order to see whether inhibition of hydroxymethylglutaryl CoA reductase is of benefit, two of our patients have been treated with simvastatin in addition to the long-term treatment with cholesterol and bile acids. Absolute as well as relative levels of DHC were reduced. In one patient, creatine kinase increased moderately after 2 months of treatment. In the other patient, the treatment had to be interrupted because of hepatotoxic side effects with a marked increase in alanine aminotransferase and aggravation of the hypocholesterolemia and photosensitivity. We conclude that even if the levels of accumulated intermediates can be reduced, treatment with a statin may be harmful in some patients with SLOS.
Adolescent↗
X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male.
X-linked dominant chondrodysplasia punctata (CDPX2; Happle syndrome) is recognized almost exclusively in females, who display mosaic and asymmetric features, presumed to arise secondary to random X-inactivation. CDPX2 results from mutation of an X-linked gene coding for sterol-delta(8)-delta(7) isomerase (emopamil binding protein). We describe a boy with clinical features of CDPX2 (including those presumed to arise usually secondary to functional mosaicism in females). Biochemical and molecular studies demonstrate that he is mosaic for a sterol-delta(8)-delta(7) isomerase gene mutation. He is the first reported example of single gene mosaicism giving rise to CDPX2 in a male.
Carrier Proteins↗
Identification of three patients with a very mild form of Smith-Lemli-Opitz syndrome.
Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive malformation syndrome characterized by mental retardation, congenital anomalies, and growth deficiency. The syndrome is caused by a block in cholesterol biosynthesis at the level of 7-dehydrocholesterol reductase (7-DHCR), which results in elevated levels of the cholesterol precursor 7-dehydrocholesterol (7-DHC) and its isomer 8-dehydrocholesterol (8-DHC). We report on three patients from two families with a very mild clinical presentation of SLOS. Their plasma cholesterol values were normal and their plasma levels of 7- and 8- DHC were only slightly elevated. In cultured skin fibroblasts, a significant residual 7-DHCR activity was found. All three patients were compound heterozygotes for a novel mutation affecting translation initiation (M1L). Two of them had the common IVS8-1G>C null mutation and the third patient an E448K mutation in the 7-DHCR gene. Our findings emphasize the importance of using a sensitive method for measuring precursors of cholesterol in combination with mutation analysis to analyze patients with only minimal clinical SLOS-like signs.
Adolescent↗
Sterol profiling of amniotic fluid: a routine method for the detection of distal cholesterol synthesis deficit.
OBJECTIVES: Smith Lemli Opitz syndrome (SLOS) caused by a deficit of 3beta-hydroxysterol-Delta7 reductase was the first sterol deficit described with multiple malformations. The lack of specificity of many morphological abnormalities detected by ultrasound and their frequency have justified routine screening of amniotic fluid (AF) for sterols by GC-MS. The examination contributes to an improved knowledge of the sterol status in the fluid. METHODS: A series of sterol profiles is collated here. Accumulation of 7- and 8-dehydrocholesterol are diagnostic for SLOS. However, a number of other sterols have also been detected by GC-MS in control AF and their presence may be confusing. RESULTS AND CONCLUSIONS: In addition to cholesterol, the level of which varies as function of the gestational age, lathosterol is present together with trace amounts of 7- and 8-dehydrocholesterol and other precursors such as desmosterol, lanosterol, and dimethylsterol. Phytosterols are also present in 70% of AF samples that have been tested. Besides SLOS, GC-MS examination of amniotic fluid can detect various sterol deficits associated with malformations (lathosterolosis, desmosterolosis, X-linked chondrodysplasia, and particular Antley-Bixler syndrome). Practical conclusions support GC-MS as a routine method to investigate skeletal and central nervous system malformations.
Amniotic Fluid↗
Cloning and functional expression in yeast of a cDNA coding for an obtusifoliol 14alpha-demethylase (CYP51) in wheat.
Screening of a wheat cDNA library with an heterologous CYP81B1 probe from Helianthus tuberosus led to the isolation of a partial cDNA coding a protein with all the characteristics of a typical P450 with high homology (32-39% identity) to the fungal and mammalian CYP51s. Extensive screening of several wheat cDNA libraries isolated a longer cDNA (W516) coding a peptide of 453 amino acids. Alignment of W516 with other P450 sequences revealed that it was missing a segment corresponding to the N-terminal membrane anchor of the protein. The corresponding segment from the yeast lanosterol 14alpha-demethylase was linked to the partial wheat cDNA and the chimera expressed in Saccharomyces cerevisiae. Compared to microsomes from control yeasts, membranes of yeast expressing the chimera catalysed 14alpha-demethylation of obtusifoliol with an increased efficiency relative to lanosterol demethylase activity. W516 is thus a plant member of the most ancient and conserved P450 family, CYP51.
Amino Acid Sequence↗
The Smith-Lemli-Opitz syndrome: a potentially fatal birth defect caused by a block in the last enzymatic step in cholesterol biosynthesis.
Explore the source record for details and available documents.
Animals↗
Reduction of BM 15.766-induced 7-dehydrocholesterol accumulation by bezafibrate and mevinolin in rats. A non-isotopic in vivo test system for compounds reducing cholesterol synthesis.
The effects of mevinolin, a 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor and bezafibrate, a modulator of lipoprotein metabolism, were measured on BM 15.766-induced 7-dehydrocholesterol (7-DHC) accumulation in liver and serum of rats. BM 15.766, an inhibitor of delta 7 sterol reductase, leads to an accumulation of 7-DHC, which can be used as a measure of cholesterol (CH) synthesis de novo. The investigations were carried out to evaluate the usefulness of this new non-isotopic in vivo method for testing compounds that affect directly and indirectly the CH-biosynthetic pathway. Mevinolin showed a dose-dependent reduction of BM 15.766-induced 7-DHC accumulation after a single oral dose. The dose range for reduction of 7-DHC in the liver of rats was comparable with that for serum CH-lowering in humans. Bezafibrate reduced the BM 15.766-induced 7-DHC accumulation in liver in a dose- and time-dependent manner. These findings agree with the reported reduced activity of HMG-CoA reductase and support the view, that bezafibrate reduces CH biosynthesis by modulation of lipoprotein metabolism. The 7-DHC levels in serum do not reflect those in the liver and cannot be used as a measure of CH biosynthesis. The investigations show that BM 15.766-induced 7-DHC accumulation in liver of rats is an appropriate measure for CH de novo synthesis and can be used for testing compounds that interfere directly and indirectly with the CH-biosynthetic pathway. In contrast to previously described methods, no radiolabelled precursors are necessary.(ABSTRACT TRUNCATED AT 250 WORDS)
Animals↗
Distribution of carotenoids and sterols in relation to the taxonomy of Taphrina and Protomyces.
Species of the genera Taphrina Fr. and Protomyces Unger were screened for the presence of carotenoid pigments and the sterols ergosterol and brassicasterol. All strains produced carotenoids in variable amounts: Taphrina: 0.3--39 micrograms/g dry weight; protomyces: 65--99 micrograms/g dry weight. It was concluded that the two genera cannot be separated on the basis of presence or absence of carotenoids. Thirty strains (24 species) of Taphrina produced brassicasterol as the principal sterol; twenty-one strains (17 species) did not form ergosterol. Only four isolates (4 species) produced ergosterol without formation of brassicasterol. Brassicasterol was the major sterol in 3 species of Protomyces, whereas ergosterol was absent. Brassicasterol is a rather unique sterol within the fungal kingdom and has hitherto not been found in the red yeasts. Therefore, this sterol is of taxonomic significance in contrast with ergosterol, which is widespread among fungi.
Ascomycota↗
The increase in skin 7-dehydrocholesterol induced by an hypocholesterolemic agent is associated with elevated 25-hydroxyvitamin D3 plasma level.
Vitamin D3 is generated in skin by UV irradiation of 7-dehydrocholesterol (7-DEHC). Whether the 7-DEHC amount in skin affects vitamin D3 formation, and thereby the plasma level of 25-hydroxyvitamin D3 (25[OH]D3) is not known. In the present work we report on the influence on vitamin D and Ca metabolism of a new hypocholesterolemic agent, HCG-917 (0-2-[hydroxy-3-]N'-(2-chlorophenyl)-N-piperazinyl-1- [propyl]-4-chloro-benz-aldoxim-hydrochloride) which inhibits 7-DEHC reductase and thereby increases skin 7-DEHC. Rats were treated with HCG 917 (0.3 and 5.0 mg/kg, orally) for 13 days. HCG 917 caused a dose-dependent decrease in cholesterol and concomitant accumulation of 7-DEHC in plasma and skin. In skin, 7-DEHC was: control: 1.05 +/- 0.20; HCG 917, 0.3 mg/kg: 1.41 +/- 0.22; HCG 917, 5.0 mg/kg: 2.35 +/- 0.35 mg/g. At a dose of 0.3 mg/kg, HCG 917 had no significant influence on the plasma level of neither 25(OH)D3 nor 1,25(OH)2D3. However, at a dose of 5.0 mg/kg, HCG 917 induced a significant increase in plasma 25(OH)D3 (control: 36.2 +/- 2.2; HCG 917 5.0 mg/kg: 57.6 +/- 6.5 nmol/l) and a slight but not significant rise in 1,25(OH)2D3. Calcium balance studies indicated that HCG 917 did not influence intestinal Ca absorption nor urinary Ca excretion. At a dose of 5.0 mg/kg HCG 917 slightly induced a decrease in total plasma Ca. In conclusion, HCG 917 treatment can induce a significant rise in skin 7-DEHC with an increase in plasma 25(OH)D3. These results suggest that variation in the skin level of 7-DEHC can directly influence the cutaneous production of vitamin D3 and thereby the vitamin D status of the organism.
Animals↗
Enzymatic conversion of 5alpha-cholest-8(14)-en-3beta-o1 to 5alpha-cholesta-8,14-dien-3beta-o1.
Explore the source record for details and available documents.
Animals↗
Inhibition of enzymatic reduction of delta 14-double bond of 5 alpha-cholesta-8,14-dien-3 beta-ol and 5 alpha-cholesta-7,14-dien-3 beta-ol by AY-9944.
AY-994 (trans-1,4-bis-(2-chlorobenzyl-aminomethyl) cyclohexane dihydrochloride), a potent inhibitor of the enzymatic reduction of the delta 7-double bond of delta 5,7-sterols, has been shown to inhibit, at higher concentrations (10-4 M), the enzymatic reduction of the delta 14-double bond of cholesta-8,14-dien-3 beta-ol and cholesta-7,14-dien-3 beta-ol.
Animals↗
Enzymatic conversion of 5alpha-cholesta-7, 14-dien-3beta-ol to 5alpha-cholesta-8, 14-dien-3beta-ol.
5alpha-Cholesta-7, 14-dien-3beta-ol, previously shown to be efficiently converted to cholesterol upon incubation with rat liver homogenate preparations under aerobic conditions, has been studied as to its possible conversion to 5alpha-cholesta-8, 14-dien-3beta-ol. Efficient conversion was observed upon incubation in the presence of washed mictosomes of rat liver under anaerobic conditions. This observation is of importance in consideration of possible metabolic pathways in the biosythesis of cholesterol.
Anaerobiosis↗